NCT02946671View on ClinicalTrials.gov

Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Gastric CancerEsophageal CancerLung CancerRenal CancerOral Cancer
Interventions
BIOLOGICAL

Mogamulizumab

Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.

BIOLOGICAL

Nivolumab

Nivolumab (3.0 mg/kg) is administered.

Trial Locations (1)

5650871

Osaka University, Suita

Sponsors
All Listed Sponsors
collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

collaborator

Clinical Study Support, Inc.

UNKNOWN

collaborator

Fiverings Co., Ltd.

OTHER

lead

Osaka University

OTHER